B41.0 Pulmonary paracoccidioidomycosis

Name of the Condition

• Pulmonary paracoccidioidomycosis

Summary

Pulmonary paracoccidioidomycosis is a fungal infection of the lungs caused by Paracoccidioides brasiliensis or Paracoccidioides lutzii. It is the most common form of paracoccidioidomycosis, a systemic disease endemic to parts of Latin America. The infection may remain localized to the lungs or progress to involve other organs, with symptoms ranging from mild respiratory complaints to severe, life-threatening disease.

Causes

The infection results from inhaling fungal spores present in soil or decaying organic matter. Once inhaled, the spores can establish infection in the lungs, where they may cause localized disease or spread to other tissues via the bloodstream. The fungus is not transmitted between people.

Risk Factors

• Residence or travel to endemic regions (e.g., Brazil, Colombia, Venezuela).
• Occupational exposure to soil or agricultural activities.
• Immunocompromised states, such as HIV/AIDS, diabetes, or chronic steroid use.
• Male gender, as the disease is more prevalent in men.
• Smoking or pre-existing chronic lung disease.

Symptoms

• Chronic cough, chest pain, or shortness of breath.
• Weight loss, fever, or night sweats.
• Skin lesions (ulcers, nodules) or mucosal involvement (oral, nasal, or laryngeal ulcers).
• Lymph node enlargement, particularly in the neck or groin.

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging (e.g., chest X-ray or CT), and laboratory testing. Microscopic examination of sputum, tissue, or body fluids may reveal the characteristic yeast form of the fungus. Cultures or molecular tests (e.g., PCR) can confirm the presence of Paracoccidioides species. Serologic tests may also be used to detect antibodies, though results can vary.

Treatment Options

Treatment usually requires antifungal medications, such as itraconazole or sulfonamides, for several months. Severe or disseminated cases may necessitate intravenous therapy (e.g., amphotericin B) initially, followed by oral agents. The duration of treatment depends on disease severity and response.

Prognosis and Follow-Up

With appropriate treatment, most patients experience improvement, but recovery may take months. Follow-up monitoring, including clinical assessments and imaging, is important to ensure resolution and detect recurrence. Immunocompromised individuals may have a higher risk of relapse and require longer treatment.

Complications

• Respiratory failure due to severe lung involvement.
• Dissemination to other organs (e.g., skin, lymph nodes, adrenal glands).
• Chronic lung damage or fibrosis.
• Secondary bacterial infections.

Lifestyle & Prevention

• Avoiding exposure to soil or dust in endemic areas, especially during activities like farming or construction.
• Using protective measures (e.g., masks) when working with soil.
• Maintaining overall health to support immune function.

When to Seek Professional Help

Seek medical attention if you experience persistent respiratory symptoms (e.g., cough, chest pain), unexplained weight loss, or skin/mucosal lesions, particularly if you have lived in or traveled to endemic regions.

Tips for Medical Coders

Use B41.0 for pulmonary paracoccidioidomycosis. Ensure documentation supports the diagnosis, including clinical findings, imaging, or laboratory confirmation of the fungal infection. Differentiate from other pulmonary fungal infections when coding.